Filing Details
- Accession Number:
- 0000899243-19-014838
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-05-28 16:01:29
- Reporting Period:
- 2019-05-23
- Accepted Time:
- 2019-05-28 16:01:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1731831 | Eidos Therapeutics Inc. | EIDX | Pharmaceutical Preparations (2834) | 463733671 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1742587 | Uma Sinha | C/O Eidos Therapeutics, Inc. 101 Montgomery Street, Suite 2550 San Francisco CA 94104 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-11-30 | 1,081 | $12.01 | 354,312 | No | 5 | A | Direct | |
| Common Stock | Disposition | 2019-05-23 | 4,200 | $27.16 | 350,112 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-05-23 | 800 | $27.88 | 349,312 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 5 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan.
- Represents the weighted average sale price of the shares sold ranging from $26.52 to $27.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Represents the weighted average sale price of the shares sold ranging from $27.55 to $28.43 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
